Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer

Cancer

Volumn 115, Issue 8, 2009, Pages 1605-1612

  Loya, Asif ^b   Guray, Merih ^c   Hennessy, Bryan T ^c   Middleton, Lavinia P ^c   Buchholz, Thomas A ^c   Valero, Vicente ^c   Sahin, Aysegul A ^a,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SHAUKAT KHANUM MEMORIAL CANCER HOSPITAL AND RESEARCH CENTRE   (Pakistan)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Axillary lymph node; Breast cancer; Cytokeratins; Pathologic complete response; Primary systemic chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKERATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CYTODIAGNOSIS; CANCER SURVIVAL; CARCINOMA CELL; DISEASE FREE SURVIVAL; FIBROSIS; FOLLOW UP; FOREIGN BODY; GIANT CELL; HISTIOCYTOSIS; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; OCCULT CANCER; OVERALL SURVIVAL; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; SEGMENTAL MASTECTOMY; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AXILLA; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; CYTODIAGNOSIS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KERATINS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL; PROGNOSIS;

EID: 65249176890     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24173     Document Type: Article

References (23)

1. Rosen PP, Groshen S. Factors influencing survival and prognosis in early breast carcinoma (T1N0M0-T1N1M0). Assessment of 644 patients with median follow-up of 18 years. Surg Clin North Am. 1990;70:937-962.
2. Fisher B, Bauer M, Wickerham DL, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer. 1983;52:1551-1557.
3. Kuerer HM, Sahin AA, Hunt KK, et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg. 1999;230:72-78.
4. Kuerer HM, Newman LA, Buzdar AU, et al. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg. 1998;176:502-509.
5. Pierga JY, Mouret E, Dieras V, et al. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer. 2000; 83:1480-1487.
6. Millis RR, Springall R, Lee AH, Ryder K, Rytina ER, Fentiman IS. Occult axillary lymph node metastases are of no prognostic significance in breast cancer. Br J Cancer. 2002; 86:396-401.
7. McGuckin MA, Cummings MC, Walsh MD, Hohn BG, Bennett IC, Wright RG. Occult axillary node metastases in breast cancer: their detection and prognostic significance. Br J Cancer. 1996;73:88-95.
8. Reed W, Bohler PJ, Sandstad B, Nesland JM. Occult metastases in axillary lymph nodes as a predictor of survival in node-negative breast carcinoma with long-term follow-up. Breast J. 2004;10:174-180.
9. Noguchi S, Aihara T, Motomura K, Inaji H, Imaoka S, Koyama H. Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Comparison between MUC1 mRNA and keratin 19 mRNA amplification. Am J Pathol. 1996;148:649-656.
10. Masuda N, Tamaki Y, Sakita I, et al. Clinical significance of micrometastases in axillary lymph nodes assessed by reverse transcription- polymerase chain reaction in breast cancer patients. Clin Cancer Res. 2000;6:4176-4185.
11. Galea MH, Athanassiou E, Bell J, et al. Occult regional lymph node metastases from breast carcinoma: immunohis-tological detection with antibodies CAM 5.2 and NCRC- 11. J Pathol. 1991;165:221-227.
12. Braun S, Cevatli BS, Assemi C, et al. Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy. J Clin Oncol. 2001;19:1468-1475.
13. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002;20:3628-3636.
14. Yared MA, Middleton LP, Smith TL, et al. Recommendations for sentinel lymph node processing in breast cancer. Am J Surg Pathol. 2002;26:377-382.
15. Wells CA, Heryet A, Brochier J, Gatter KC, Mason DY. The immunocytochemical detection of axillary micrometa- stases in breast cancer. Br JCancer. 1984;50:193-197.
16. Trojani M, de Mascarel I, Coindre JM, Bonichon F. Micrometastases to axillary lymph nodes from invasive lobular carcinoma of breast: detection by immunohistochemistry and prognostic significance. Br JCancer. 1987;56:838-839.
17. Clare SE, Sener SF, Wilkens W, Goldschmidt R, Merkel D, Winchester DJ. Prognostic significance of occult lymph node metastases in node-negative breast cancer. Ann Surg Oncol. 1997;4:447-451.
18. Prognostic importance of occult axillary lymph node micro- metastases from breast cancers. International (Ludwig) Breast Cancer Study Group. Lancet. 1990;335:1565-1568.
19. Liberman L. Pathologic analysis of sentinel lymph nodes in breast carcinoma. Cancer. 2000;88:971-977.
20. Hainsworth PJ, Tjandra JJ, Stillwell RG, et al. Detection and significance of occult metastases in node-negative breast cancer. Br J Surg. 1993;80:459-463.
21. Cummings MC, Walsh MD, Hohn BG, Bennett IC, Wright RG, McGuckin MA. Occult axillary lymph node metastases in breast cancer do matter: results of 10-year survival analysis. Am J Surg Pathol. 2002;26:1286-1295.
22. Colpaert C, Vermeulen P, Jeuris W, et al. Early distant relapse in "node-negative" breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumour. J Pathol. 2001;193:442-449.
23. Hennessy BT, Hortobagyi GN, Rouzier R, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol. 2005;23:9304-9311.